【摘要】 目的综述目前非小细胞肺癌靶向辅助医治和针对T790M突变、EGFR exon 20ins突变的医治以及靶向联合治疗模式的研究现状及进展。方法回顾和分析了近3年国内外的研究文献,讨论非小细胞肺癌靶向治疗研究的相关进展,并对其进行归纳、整理和总结。结果ADAURA研究的成功说明了辅助化疗序贯EGFR-TKI有望成为一种有效的治疗模式,在T790M突变以及EGFRexon20ins突变导致耐药的治疗方面,新型靶向药物不断研发并相继投入到临床试验,目前已取得了较好的试验结果。靶向治疗的模式从一开始的单药策略逐渐过渡到多药联合的治疗模式,已取得了不菲的成就。结论 EGFR靶向治疗在非小细胞肺癌的治疗中有着重要的临床意义以及发展前景。更多还原

【Abstract】 Objective To review the current research progress of targeted adjuvant therapy for non-small cell lung cancer(NSCLC), treatment for T790 M mutation, EGFR exon 20 ins mutation and targeted combination therapy. Methods Recent domestic and foreign literatures were reviewed and analyzed, and the relevant progress of targeted therapy for NSCLC was discussed and summarized. Results The success of the ADAURA study shows that adjuvant chemotherapy sequential EGFR-TKI is expected to become an effective treatment mode. For the treatment of drug resistance caused by T790 M mutation and EGFR exon 20 ins mutation, new targeted drugs have been continuously developed and put into clinical trials, and good test results have been achieved. Based on good test results, the targeted therapy model has gradually transitioned from a single-drug strategy to a multi-drug combination therapy model, and has achieved significant results. Conclusions EGFR-targeted therapy has important clinical significance and development prospect in the treatment of NSCLC.更多还原